Drug intelligence / Profile preview

SHR-8203

Development stage: Phase 2
Lead developer: Beijing Suncadia Pharmaceuticals

Overview

SHR-8203 is an investigational therapeutic candidate being developed by Beijing Suncadia Pharmaceuticals (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of advanced solid tumors. It is formulated as an injection and is classified as a Class 1 therapeutic biologic in China. In 2026, a Phase I/II open-label, multi-center clinical trial (CTR20263142) was registered to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SHR-8203 in patients with advanced solid tumors. The specific biological target and mechanism of action of SHR-8203 have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SHR-8203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-8203.

Explore the full profile